Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy

Sarepta Therapeutics faces significant regulatory setbacks as the FDA has placed a clinical hold on all its investigational limb girdle muscular dystrophy (LGMD) trials and revoked its gene therapy platform technology designation. This action stems from three patient deaths, including two on approved Elevidys and one in an LGMD trial (SRP-9004), all linked to acute liver failure, raising serious safety concerns about the company's AAVrh74 viral vector. The FDA's move disrupts Sarepta's LGMD pipeline, notably SRP-9003 which was nearing BLA submission, and highlights escalating regulatory scrutiny, particularly given Sarepta's prior non-disclosure of a trial death and refusal to halt Elevidys shipments.

Analysis

Sarepta Therapeutics is facing a severe regulatory and safety crisis following the FDA's imposition of a clinical hold on its entire limb girdle muscular dystrophy (LGMD) trial portfolio and the revocation of its AAVrh74 platform technology designation. The FDA's action was triggered by a third patient death, this one in an LGMD trial for SRP-9004, which follows two deaths in patients treated with the approved Duchenne muscular dystrophy (DMD) therapy, Elevidys. Critically, all three fatalities were linked to acute liver failure, suggesting a systemic safety issue with the underlying AAVrh74 viral vector technology rather than an asset-specific problem. This development significantly jeopardizes Sarepta's pipeline, particularly the advanced candidate SRP-9003, for which the company had planned a biologics license application (BLA) in the second half of this year. The situation is exacerbated by a deteriorating relationship with the regulator, evidenced by Sarepta's initial non-disclosure of the LGMD trial death—which CEO Douglas Ingram deemed not "material"—and the company's subsequent refusal of an FDA request to voluntarily halt shipments of Elevidys. This confrontational stance, combined with the FDA's strong public statement about "unreasonable and significant risk," introduces substantial uncertainty regarding the future of both the investigational pipeline and the commercialized Elevidys.

Key Decisions for Investors

• Investors should immediately re-evaluate the risk profile of Sarepta's entire gene therapy platform, as the recurring issue of fatal acute liver failure across different programs suggests a fundamental flaw in the AAVrh74 vector, potentially jeopardizing the long-term commercial viability of Elevidys.
• The clinical hold introduces indefinite delays for the entire LGMD pipeline, and the value attributed to near-term catalysts, such as the now-unlikely H2 BLA submission for SRP-9003, should be significantly discounted or removed from valuation models pending a clear resolution pathway.
• Monitor the escalating conflict between Sarepta and the FDA, as the company's lack of transparency regarding the patient death and its refusal to halt Elevidys shipments create significant governance risk and could provoke further, more severe regulatory actions.